An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Various corners of the media and internet are hyperventilating over the alleged genetic privacy implications of the imminent ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

A surprising mix of inherited and de novo mutations in 60 genes contribute to 10 percent of CHD cases. Many of these same ...

Genetic testing company 23andMe’s bankruptcy has led to a new consumer privacy issue: what happens to the DNA of millions of ...

A test for abnormal fetal chromosomes can also detect maternal cancers—and physicians are struggling to incorporate that ...

Swedish researchers have identified genetic variants that increase the risk of atherosclerosis. The aim is for these new findings to enable earlier detection of atherosclerosis and improved treatment ...

Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...

Research shows that some athletes may inherit a higher risk of heart disease, even if they appear fit. Tamim Iqbal's brother, former cricketer Nafees Iqbal, for instance, suffered a brain stroke in ...

High Lipoprotein (a) is a genetic condition that increases the risk of early heart attacks and strokes. It is one of the most common genetic risk factors for cardiovascular disease, yet it remains ...

While it's not 100 percent clear if the "delete your DNA" calls were warranted, privacy experts are alarmed, and Americans who had taken the genetic test took the advice to heart. According to ...